Advertisement
ARRY vs CDXS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Hold and CDXS is a StrongBuy.
ARRY's RSI Indicator ascends from oversold territory
The RSI Oscillator for ARRY moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 33 of the 37 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 194 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
ARRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARRY as a result. In 82 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ARRY turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 38 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ARRY entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.599) is normal, around the industry mean (2.617). P/E Ratio (-3.552) is within average values for comparable stocks, (5.265). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.057) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ARRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
CDXS's Stochastic Oscillator stays in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in 226 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CDXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXS as a result. In 84 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CDXS turned negative on October 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CDXS entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.286) is normal, around the industry mean (2.988). P/E Ratio (-3.909) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1.588) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CDXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARRY | CDXS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 88 | 84 | |
P/E GROWTH RATING 1..100 | 11 | 12 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (11) in the Biotechnology industry is somewhat better than the same rating for CDXS (58) in the Chemicals Specialty industry. This means that ARRY’s stock grew somewhat faster than CDXS’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that ARRY’s stock grew similarly to CDXS’s over the last 12 months.
CDXS's SMR Rating (98) in the Chemicals Specialty industry is in the same range as ARRY (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to ARRY’s over the last 12 months.
CDXS's Price Growth Rating (84) in the Chemicals Specialty industry is in the same range as ARRY (88) in the Biotechnology industry. This means that CDXS’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (11) in the Biotechnology industry is in the same range as CDXS (12) in the Chemicals Specialty industry. This means that ARRY’s stock grew similarly to CDXS’s over the last 12 months.
| ARRY | CDXS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 77% | about 1 month ago 83% |
| Declines ODDS (%) | 4 days ago 89% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 2 FA rating(s) are green while CDXS’s FA Score has 1 green FA rating(s).
- ARRY’s FA Score: 2 green, 3 red.
- CDXS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 4 TA indicator(s) are bullish while CDXS’s TA Score has 3 bullish TA indicator(s).
- ARRY’s TA Score: 4 bullish, 4 bearish.
- CDXS’s TA Score: 3 bullish, 4 bearish.
Price Growth
ARRY (@Alternative Power Generation) experienced а +0.89% price change this week, while CDXS (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was -4.69%. For the same industry, the average monthly price growth was -14.82%, and the average quarterly price growth was -40.36%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
ARRY is expected to report earnings on Nov 05, 2026.
CDXS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Alternative Power Generation (-4.69% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CDXS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To CDXS | 1D Price Change % | ||
|---|---|---|---|---|
| CDXS | 100% | +4.88% | ||
| AXON - CDXS | 43% Loosely correlated | +2.54% | ||
| VCYT - CDXS | 39% Loosely correlated | +3.19% | ||
| ARRY - CDXS | 36% Loosely correlated | +2.40% | ||
| TNYA - CDXS | 36% Loosely correlated | -4.83% | ||
| ZVRA - CDXS | 35% Loosely correlated | -1.05% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| USAX | 3.44 | 0.14 | +4.24% |
| Tradr 2X Long USAR Daily ETF (USAX) | |||
| DIVI | 42.68 | 0.14 | +0.33% |
| Franklin International Core Dividend Tilt Index Fund (DIVI) | |||
| MSFU | 42.10 | 0.10 | +0.24% |
| Direxion Daily MSFT Bull 2X ETF (MSFU) | |||
| MAYM | 33.42 | 0.03 | +0.09% |
| FT Vest U.S. Equity Max Buffer ETF - May (MAYM) | |||
| SPYA | 31.04 | N/A | N/A |
| Twin Oak Endure ETF (SPYA) | |||